These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
16. Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease. Lantero-Rodriguez J; Salvadó G; Snellman A; Montoliu-Gaya L; Brum WS; Benedet AL; Mattsson-Carlgren N; Tideman P; Janelidze S; Palmqvist S; Stomrud E; Ashton NJ; Zetterberg H; Blennow K; Hansson O Mol Neurodegener; 2024 Feb; 19(1):19. PubMed ID: 38365825 [TBL] [Abstract][Full Text] [Related]
17. Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau. Janelidze S; Palmqvist S; Leuzy A; Stomrud E; Verberk IMW; Zetterberg H; Ashton NJ; Pesini P; Sarasa L; Allué JA; Teunissen CE; Dage JL; Blennow K; Mattsson-Carlgren N; Hansson O Alzheimers Dement; 2022 Feb; 18(2):283-293. PubMed ID: 34151519 [TBL] [Abstract][Full Text] [Related]
18. Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios. Janelidze S; Barthélemy NR; He Y; Bateman RJ; Hansson O JAMA Neurol; 2023 May; 80(5):516-522. PubMed ID: 36987840 [TBL] [Abstract][Full Text] [Related]
20. Effects of certain pre-analytical factors on the performance of plasma phospho-tau217. Bali D; Hansson O; Janelidze S Alzheimers Res Ther; 2024 Feb; 16(1):31. PubMed ID: 38331843 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]